Prostate cancer is a major public health concern. Globally, prostate cancer is the fourth most common cancer (all genders) and the second most common cancer in men.1,2 In the United States, approximately one man in nine will be diagnosed with prostate cancer in his lifetime.3 Approximately 70% of prostate cancer cases are low risk, yet up to 90% are treated aggressively.4
We offer a wide menu of immunohistochemistry (IHC) assays. Our portfolio of products delivers the high sensitivity and specificity you need.
Our antibodies are ready-to-use on the fully automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions. We have a robust assay development program focusing on immunohistochemical staining, clinical reagents, cancer diagnostic assays and much more.